Portola and Boehringer find antidotes to poor oral anticoagulant uptake
This article was originally published in Scrip
Executive Summary
Portola Pharmaceuticals and Boehringer Ingelheim have reported strong late-stage data supporting the upcoming filings for their long-awaited anticoagulant antidotes, andexanet alfa and idarucizumab.